anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The goal of this study is for the recipients of a living related kidney transplant of one HLA haplotype to be withdrawn of immunosuppressive medication and become "tolerant "to their kidney graft. The recipient will receive a conditioning regimen composed of low dose radiation to the lymphoid tissue (total lymphoid irradiation, TLI) and anti-thymocyte globulin (ATG) at the time of transplant. They will then be infused with purified "stem cell" and T-cell from their kidney donors 2 weeks after the transplant to try to achieve mixed chimerism of their white blood cells with the donor (the recipient would have a mixture some of the with blood cells of the donor and theirs in their blood). The kidney donor has to provide peripheral stem cell 6-8 weeks before kidney donation. It is an outpatient procedure done using peripheral veins after treatment with G-CSF (filgrastim).Immunosuppressive medication will be decreased gradually and possibly stopped by 1 1/2 year after the transplantation if the recipient meets withdrawing criteria (persistence of mixed chimerism more than 18 months, no episode of rejection and no rejection on surveillance kidney biopsy). Potential candidates need to be approved for kidney transplant and available for close follow-up at Stanford University Medical Center.
FIELD: medicine, traumatology, orthopedics. SUBSTANCE: method involves carrying out an ultrasonic sanitation of pathological focus through 3-5% solution of ethylenediaminetetraacetic acid disodium salt used as contact medium. Treatment course is 14-21 days. Method provides lysis of small sequesters and sanitation of inflammatory focus. Invention can be used for treatment of fistulous form of chronic osteomyelitis with small sequesters. EFFECT: enhanced effectiveness of treatment. 2 cl, 2 dwg, 2 ex
INTRODUCTION: Anticoagulants play a vital role as part of the antithrombotic therapy of myocardial infarction and are complementary to antiplatelet therapies. In the acute setting, the rationale for their use is to antagonize the ongoing clotting cascade including during percutaneous coronary intervention. Anticoagulation may be an important part of the longer-term antithrombotic strategy especially in patients who have other existing indications (e.g. atrial fibrillation) for their use.
AREAS COVERED: In this narrative review, the authors provide a contemporary summary of the anticoagulation strategies of patients presenting with NSTEMI, both in terms of anticoagulation during the acute phase as well as suggested antithrombotic regimens for patients who require long-term anticoagulation for other indications.
EXPERT OPINION: Patients presenting with non-ST-elevation myocardial infarction (NSTEMI) should be initiated on anticoagulation (e.g. heparin/low molecular weight heparin) for the initial hospitalization period for those medically managed or until percutaneous coronary intervention. Longer term management of NSTEMI for patients with an existing indication for long-term anticoagulation should comprise triple antithrombotic therapy of anticoagulant (preferably DOAC) with aspirin and clopidogrel for up to 1 month (typically 1 week or until hospital discharge), followed by DOAC plus clopidogrel for up to 1 year, and then DOAC monotherapy thereafter.
Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment approach for patients with relapsed/refractory non-Hodgkin lymphoma (R/R NHL). However, the long-term prognosis has been discouraging. Moreover, the urgent resolution of two critical issues is necessary: minimize tumor burden before CAR-T infusion and control fatal toxicities post CAR-T therapy. By combining radiotherapy (RT), the safety and efficacy of CAR-T can be improved. RT can serve as bridging therapy, reducing the tumor burden before CAR-T infusion, thus enabling safe and successful CAR-T infusion, and as salvage therapy in cases of CAR-T therapy failure. This review aims to discuss the current evidence supporting the use of RT in CAR-T therapy for patients with R/R NHL. Although most studies have shown a positive role of RT in combined modality treatments for patients undergoing CAR-T therapy, the synergy gained from these remains uncertain. Furthermore, the optimal dose/fraction and radiation response require further investigation.
This disclosure relates to method and system determining a plurality of patient health indicators through a Machine Learning (ML) model. The method includes receiving numerical data from a monitoring device. The numerical data is based on patient input data. The patient input data includes predefined variables, discretely sampled data, and continuously sampled data. The method further includes identifying a set of patterns from the numerical data through the ML model. The ML model is based on at least one of a Long Short Term Memory (LSTM), Extreme Gradient Boost (XGBoost), and Transformers. The method further includes comparing the set of patterns with historical medical data of the patient. The method further includes determining the plurality of patient health indicators through the ML model based on the comparing.
Patients receive romidepsin IV over 4 hours on days 1, 8, and 15 and lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
The intervention will be a home-based total-body exercise training program (prehabilitation) based on a protocol with proven efficacy in improving the function of non-frail surgical patients in less than 4 weeks of preoperative utilization.Prehabilitation will consist of 3 components: 1) strength training; 2) aerobic exercise and 3) flexibility. Prehabilitation will be prescribed as 1-hour sessions performed a minimum of 3 times per week. Intervention group patients will also be provided with nutritional advice. In addition to paper-based materials outlining the prehabilitation program, weekly prehabilitation teaching sessions will be held at our Cancer Centre for patients randomized to the intervention group, and activity logs and weekly phone calls will be used to measure compliance and to answer questions. During the final week of the program, patients will also participate in a brief qualitative interview over the phone to explore their experience with the program.
Psilocybin (10mg) will be administered one time orally as a capsule taken with water. Expected duration of acute effects is approximately 6 hours. After a period of a washout, participants will switch to the placebo intervention.
Standard system use for 6 months. Followed by open access to the device for 6 months.
BACKGROUND: Chronic low back pain (CLBP), a significant cause of disability, is expected to increase with aging. Short Form 36 (SF-36) indicated higher baseline component scores predict CLBP disability at shorter follow-ups, with unexplored five-year associations. The study aimed to test the associations of the physical and mental subscales of the SF-36 at baseline with disability at the five-year follow-up point among patients with CLBP.
METHODS: Patients aged between 20 and 65 years with CLBP were enrolled at baseline and followed at the five-year point. The Oswestry Disability Index (ODI), the physical functioning (PF) subscale of the SF-36, and self-reported total months of disability (TMOD) over the past five years were used as the indices of disability. The four physical and mental subscales of the SF-36 were used as independent factors, respectively. Multiple linear regression was used to compare the associations of the physical and mental subscales at baseline with disability at follow-up.
RESULTS: Two hundred twenty-five patients with CLBP were enrolled at baseline and 111 participated in followed at the five-year point. Among the SF-36 subscales, the scores of bodily pain (BP), vitality (VT), and social functioning (SocF) at baseline were significantly correlated with the three indices of disability at follow-up. After controlling for demographic and clinical variables, BP and VT at baseline were most strongly associated with the ODI and TMOD at follow-up among the four physical and mental subscales, respectively. PF at baseline was most strongly associated with itself at follow-up among the four physical subscales.
CONCLUSION: Our results demonstrated that both the physical and mental subscales of the SF-36 at baseline could predict disability at the five-year follow-up point among patients with CLBP. The BP and VT subscales were independent factors associated with disability among the physical and mental subscales, respectively.
The present invention relates to the improvement of phagocytosis. In this study, the inventors demonstrate that HRV16 impairs macrophage phagocytosis of multiple targets. This was not due to a global dysregulation of the actin cytoskeleton. They report that HRV16 induced a down-regulation of Arpin in macrophages. By re-expressing Arpin in a model cellular system where HRV16 exposure led to decreased internalisation they could rescue this defect. Based on these results they postulated that Arpin is necessary for phagocytosis. Further analysis revealed that Arpin is required for efficient phagosome formation. Thus, Arpin plays a critical role in coordinating and orchestrating actin remodelling around internalised particles necessary for efficient phagocytosis. Therefore, they add phagocytosis to the growing list of functions being attributed to Arpin and highlight a host cell factor specifically targeted by rhinovirus. Thus the invention relates to an Arpin protein or fragment thereof and/or an agent for Arpin protein expression for use in the improvement of phagocytosis in a subject in need thereof.
<P>PROBLEM TO BE SOLVED: To provide a new magnetic fine particle-containing dosage form, a method for producing the same and a magnetic fine particle-containing preparation.  <P>SOLUTION: This magnetic fine particle-containing dosage form 10 includes a molecular aggregate 1, a coating magnetic fine particle-containing membrane 2 for covering the molecular aggregate 1 and containing the magnetic fine particles 3. A pharmaceutical agent can be incorporated in at least any of the molecular aggregate 1 and the covering magnetic fine particle-containing membrane 2. The magnetic fine particle-containing preparation 100 includes the fine magnetic particle-containing dosage form 10 and a compound organizer 40 for forming an associated body with the same. In the compound organizer 40, a pharmaceutical agent can be incorporated. Suitable examples of the molecular aggregate 1 can include micelle and liposome.  <P>COPYRIGHT: (C)2011,JPO&INPIT
Background: Alcohol is the most consumed psychoactive substance in Spain. In 2016 it was the seventh leading risk factor for death and disability-adjusted lost years worldwide, and the first one in people between 15 and 49 years old.In the scientific community there is some controversy about what would be the best approach to face this great problem. On the one hand, there is evidence to recommend that there is no safe level of alcohol. However, on the other hand, there are studies that demonstrate the protective role of a moderate alcohol consumption. In this pilot study both options will be compared.

Methods: It is intended to recruit a total of 100 participants, including two observational cohorts of abstainers and drinkers. The intervention will be carried out in drinkers willing to change their alcohol consumption, divided into 2 groups of 50 participants, the abstention group and the Mediterranean alcohol-drinking pattern group. The Mediterranean alcohol-drinking pattern includes 5 aspects: moderate alcohol consumption (maximum of 1 drinks/day for women and 2 drinks/day for men), spread consumption throughout the week, drink with meals and never with an empty stomach, prefer wine and mainly red wine, as well as completely avoid episodes of binge-drinking. The main objective will be to compare the short and medium term effects on health of both patterns.
The present invention provides a TOP2A inhibition by temozolomide useful for predicting glioblastoma patient's survival. Glioblastoma (GBM) is the most common, malignant primary adult brain tumor. The conventional treatments for GBM, include surgery, radiation, and chemotherapy which have only modestly improved patient survival. The patients with GBM expressing higher TOP2A transcript levels had better prognosis. More interestingly, the present invention reports that temozolomide is an inhibitor of TOP2A activity  in vitro . The present invention further shows that siRNA knock down of TOP2A rendered a glioma cell line resistant to temozolomide chemotherapy. Thus it is demonstrated for the first time that temozolomide is a TOP2A inhibitor and establishes that TOP2A transcript levels determines the chemosensitivity of glioblastoma to temozolomide therapy thus explaining the very high levels of TOP2A transcript being a good prognostic indicator in GBM patients receiving temozolomide chemotherapy.
Solid readily dispersable preparations containing procaine penicillin are manufactured by intimately mixing (e.g. by trituration) procaine penicillin with a small amount (e.g. 0.1-1.0 per cent), of a water-soluble non-ionic surface-active agent in the presence of an organic solvent selected from lower aliphatic alcohols, ketones and chlorinated hydrocarbons, aliphatic carboxylic acid esters and aromatic hydrocarbons, and having a boiling point not substantially above 130 DEG  C., at normal pressure, the organic solvent being thereafter removed, e.g. by the action of heat.  Suitable solvents include methyl and n-butyl alcohol, ethyl, n- and isopropyl and n-butyl acetate, chloroform, carbon tetrachloride, dichlorethylene and especially acetone, whilst preferred surface-active agents are the polyoxyalkylene derivatives of partial esters of polyhydric alcohols having at most 10 hydroxy groups with fatty acids having at least 4 carbon atoms in the molecule, especially a polyoxyalkylene derivative of a hexitol inner anhydride partial long-chain fatty acid ester.  In examples, the surface-active agent is polyoxyethylene sorbitan mono-oleate, alternatives to which are listed. Specifications 661,272 and 3806/46 (as open to inspection under Sect. 91) are referred to.ALSO:Solid readily dispersable preparations containing procaine penicillin are manufactured by intimately mixing (e.g. by trituration), procaine penicillin with a small amount (e.g. 0.1-1.0 per cent), of a water-soluble non-ionic surface active agent in the presence of an organic solvent selected from lower aliphatic alcohols, ketones and chlorinated hydrocarbons, aliphatic carboxylic acid esters and aromatic hydrocarbons, and having a boiling point not substantially above 130 DEG C at normal pressure, the organic solvent being thereafter removed, e.g. by the action of heat.  The products, which may be distributed in vials, yield injectible suspensions by dispersing them in an injectible menstruum, especially water. Suitable organic solvents include methyl and n-butyl alcohol, ethyl, n-and iso-propyl and n-butyl acetate, chloroform, carbon tetrachloride, dichlorethylene and especially acetone, whilst preferred surface active agents are the polyoxyalkylene derivatives of partial esters of polyhydric alcohols having at most 10 hydroxy groups with fatty acids having at least 4 carbon atoms in the molecule, especially a polyoxyalkylene derivative of a hexitol inner anhydride partial long chain fatty acid ester.  In examples, the surface active agent is polyoxyethylene sorbitan monooleate, alternatives to which are listed.  Specifications 661,272 and 3806/46 (as open to inspection under Sect. 91), are referred to.
The invention relates to a conditionally replicating oncolytic adenoviral vector used for expressing two exogenous genes and modified by small peptide. Specifically, base 1083bp is deleted in the section of 2245bp-3327bp of human adenovirus type 5 genome, and an expression element expressing a first exogenous gene is inserted into the section of 2245bp-3327bp of human adenovirus type 5 genome. And at 32679bp of adenovirus type 5 genome, i.e. at the position of fibrin HI loop, a code containing a small peptide is inserted. A second exogenous gene of dual expression and an eGFP expression element are inserted into the section of 32787bp-32788bp of human adenovirus type 5 genome. The construction method of the vector includes the steps of: constructing a shuttle missed by pAd5E1B 55kd, constructing a shuttle of the first exogenous gene pHE1B55D-, constructing an adenoviral vector backbone of the first exogenous gene pHE1B55D-/SwaI, constructing a shuttle of the small peptide sequence pshuttle Ad5-E4-fiber-, constructing a shuttle expressing eGFP and the second exogenous gene, and preparing the conditionally replicating oncolytic adenoviral vector used for expressing two exogenous genes and modified by small peptide. The invention also provides the application of the adenoviral vector provided in the invention in preparing medicaments for treating tumours.
This is an open-label (both investigator and volunteer knows the name of the assigned study medication), randomized (study medication will be assigned by chance) cross-over study in healthy adults to compare the rate and the extent of absorption of TMC278 when administered as a single 25 mg dose of the 3 concept pediatric formulations (solution \[10 mg/mL\], suspension \[5 mg/mL\], granules \[2.5 mg/g\]), under fed and fasted conditions, to that when administered as the 25 mg TMC278 Phase III tablet formulation, under fed conditions, in healthy adults and to assess the effect of food on the bioavailability of TMC278 after a single 25 mg dose of the concept pediatric TMC278 formulations in healthy adults. The palatability of the 3 concept formulations will be assessed in a fasted state by use of a questionnaire and a visual analog scale. The short-term safety and tolerability of TMC278 following administration of 3 single oral doses of 25 mg, formulated as one of the concept pediatric formulations (under fed and fasted conditions) and as the Phase III tablet (under fed conditions), in healthy adults will be evaluated. TMC278 25 mg formulated as a solution, suspension, granules, or tablet will be administered orally (by mouth). Each volunteer will receive on the first day of one treatment session one TMC278 25 mg tablet. On the first day of the other sessions they receive a single dose of TMC278 25 mg formulated as a the solution, a suspension or granules.
BACKGROUND: Gallbladder polyps are increasingly being identified due to the widespread use of abdominal ultrasound imaging. They are concerning lesions due to their potential malignant risk. It is hoped that managing them correctly will play a role in improving poor survival rates of gallbladder cancer. Awareness of these lesions is lacking. Management continues to be guided by expert opinion and observational studies and a number of consensus statements exist.
OBJECTIVE: This paper reviews and summarises the current literature and provides an approach for general practitioners based on the available guidance.
DISCUSSION: Although minor variation exists between consensus statements, the risk of malignancy for gallbladder polyps is still largely dictated by size, with those ≤5 mm generally considered to pose little risk and not requiring follow-up, whereas those ≥10 mm considered at greater risk and requiring referral for cholecystectomy.
Participants will perform the novel stretch in a supine position. Participants will place a small ball between their knees and squeeze the ball. Participants will be then bridge as high as possible . Participants will then flex their shoulder and elbow to 90°, and actively rotate to the end of ROM. Participants will use the other hand to push to the point of mild discomfort and simultaneously maintain contraction while progressing the stretch.
The patients in this group will be treated by the MCIC technique, which uses concentrated BMAC to regenerate articular cartilage. MCIC is a single stage arthroscopic procedure. It is done as a day case procedure. BMAC is harvested intraoperatively and concentrated. It is then mixed with a fibrin gel and implanted under CO2 insufflation.
In Part A, approximately 24 patients will be randomized to one of four different treatment groups. After a 7-day washout of riluzole, patients in each treatment group will receive daily oral doses of placebo, 125 mg, 250 mg, or 375 mg of CK-2017357 for 14 days. Patients will take daily doses of CK-2017357 or placebo (Day 1 through Day 14) and will return to the study site on Day 2, Day 8 and Day 15. All patients will return for a follow-up visit 7 days (± 2 days) after their last dose.

In Part B, approximately additional 24 patients will be randomized to one of four different treatment groups as in Part A. Patients in Part B will be required to decrease their riluzole dose to 50 mg once a day (QD) for 7 days prior to randomization. After this 7 day period, patients will take riluzole at 50 mg QD concurrently with their morning dose of blinded study drug.
Chronic kidney disease (CKD) guidelines recommend early identification and intervention to delay the progression of CKD. The Kidney Disease: Improving Global Outcomes (KDIGO) heatmap is widely used for risk evaluation in CKD management; however, real-world evidence on clinical characteristics based on the KDIGO heatmap remains limited worldwide including Japan. In order to understand the management of CKD including its diagnostic rates in a Japanese clinical setting on the basis of KDIGO heatmap, we utilized a medical record database that contains estimated glomerular filtration rate (eGFR) and urine protein data. Adult individuals (≥ 18 years) with two eGFR results of < 90 mL/min/1.73 m2, 90-360 days apart, were included. Approximately half of patients (452,996/788,059) had proteinuria test results and 6.9% (54,073) had quantitative results. CKD diagnosis rate in patients without proteinuria data was 5.9%, with a lower rate (2.9%) in stage G2; the corresponding rates with quantitative test results were 43.5% and 31.3%, respectively. The most frequent comorbidities were hypertension, diabetes, and cardiovascular disease, and their prevalence increased as the eGFR and proteinuria stages progressed. This study revealed a low rate of proteinuria assessment, especially using quantitative methods, and diagnosis in individuals with suspected CKD. With emerging treatment options to prevent CKD progression and complication onset, there is a need for early evaluation and diagnosis of CKD.
Nuclear Factor NF-.kappa.B is a protein specific to B cells, binds to a specific DNA sequence within the immunoglobin light chain .kappa. locus enhancer region, and plays a central role in various responses, due to rapid induction of gene expression. NF-.kappa.B controls the expression of various inflammatory cytokines, the major histocompatibility complex genes, and adhesion molecules involved in tumor metastasis.  The present invention is drawn to the inhibition of activation of NF-.kappa.B  by caffeic acid phenethyl ester (CAPE) and two analogues of CAPE. Tumor necrosis factor (TNF) activation of NF-.kappa.B is completely blocked by CAPE in a dose- and time-dependent manner, as is activation by phorbol ester, ceramide, hydrogen peroxide, and okadaic acid.  Additionally, capsaicin (8-methyl-N-vanillyl-6-nonenamide) and resiniferatoxin inhibit the activation of NF-.kappa.B induced by different agents. Further, the present invention discloses methods for using these inhibitors in the treatment of pathological conditions caused by the activation of NF-.kappa.B, such as toxic shock, acute inflammatory conditions, acute phase response, atherosclerosis and cancer.